What question did this study set out to answer?

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates overall survival in transplant-ineligible relapsed diffuse large B-cell lymphoma, indicating a promising treatment option.

Evaluate the efficacy and safety of Polatuzumab Vedotin plus Rituximab, Gemcitabine, and Oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma.
Randomized, open-label, phase III trial with 255 patients assigned to either Pola-R-GemOx or R-GemOx every 21 days.
Patients were transplant-ineligible and received treatment for up to eight cycles, following a safety run-in.
The primary endpoint focused on overall survival.
Patients receiving Pola-R-GemOx had a median overall survival of 19.5 months compared to 12.5 months for R-GemOx (hazard ratio 0.6, 95% CI 0.43 to 0.83, P=0.0017).
Common grade 3/4 adverse events included thrombocytopenia and neutropenia, with peripheral neuropathy more frequent in the Pola-R-GemOx group (57% vs 29%).
Fatal adverse events were higher in the Pola-R-GemOx group (12%) compared to R-GemOx (4%), primarily due to infections.

Matasar et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates overall survival in transplant-ineligible relapsed diffuse large B-cell lymphoma, indicating a promising treatment option.